Hyperfine Gestione
Criteri Gestione verificati 2/4
Hyperfine Il CEO è Maria Degois-Sainz, nominato in Oct2022, e ha un mandato di 3.58 anni. la retribuzione annua totale è $ 896.82K, composta da 64.9% di stipendio e 35.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.04% delle azioni della società, per un valore di $ 58.98K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 4.4 anni.
Informazioni chiave
Maria Degois-Sainz
Amministratore delegato
US$896.8k
Compenso totale
| Percentuale dello stipendio del CEO | 64.92% |
| Mandato del CEO | 3.6yrs |
| Proprietà del CEO | 0.04% |
| Durata media del management | 1.5yrs |
| Durata media del Consiglio di amministrazione | 4.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • May 20
HYPR: European Regulatory Wins And New Loan Facility Will Support Upside
Analysts have raised their price target for Hyperfine from $1.60 to $2.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What's in the News Reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this implies 55% growth at the midpoint compared with 2025 (company guidance).Articolo di analisi • May 15
Hyperfine, Inc. (NASDAQ:HYPR) Analysts Are Pretty Bullish On The Stock After Recent Results
Hyperfine, Inc. ( NASDAQ:HYPR ) just released its quarterly report and things are looking bullish. Revenues were better...Aggiornamento della narrazione • Apr 30
HYPR: European Approvals And New Financing Will Support Future Upside Potential
Analysts have raised their price target on Hyperfine by $0.30, citing updated fair value assumptions of $1.60 per share that reflect adjusted expectations for revenue growth, profit margins, discount rate, and a higher future P/E multiple. What's in the News Received CE Marking and UK Conformity Assessment approval for the next generation Swoop portable MRI system and the latest Optive AI software, allowing commercialization across Europe and the UK.
Aggiornamento della narrazione • Apr 16
HYPR: European Approvals And Clinical Evidence Will Drive Future Upside
Analysts now set a $2.05 price target for Hyperfine, unchanged from before, reflecting updated views on discount rate, profit margin, and expected future P/E, without a shift in the overall valuation level. What's in the News Hyperfine received CE Marking and UKCA approval for its next generation Swoop system and latest Optive AI software, clearing the way for commercialization of its portable MRI technology across Europe and the UK and broadening its international reach in brain imaging (Product related announcement).Aggiornamento della narrazione • Apr 01
HYPR: Growing Clinical Evidence In Stroke And Outpatient Care Will Drive Upside
Analysts have lifted their Hyperfine price target from $1.65 to $2.05, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that adjust the stock's risk and earnings outlook in their models. What’s in the News Entered a new loan and security agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to US$40 million, including an initial US$15 million draw and the option to access an additional US$25 million through December 31, 2027, with interest only payments through March 18, 2031 (Key Developments).Aggiornamento della narrazione • Mar 18
HYPR: Expanding Stroke And Outpatient Evidence Will Support Future Upside
Analysts have maintained their $1.65 price target for Hyperfine, citing largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for this view. What's in the News The largest data set to date for stroke detection with the Swoop system reported strong evidence supporting AI powered portable MRI for ischemic stroke detection in emergency and other clinical settings.Aggiornamento della narrazione • Mar 04
HYPR: Expanding Clinical Evidence And New Trials Will Support Future Upside
Analysts have kept their price target for Hyperfine steady at $1.65, with small tweaks to assumptions such as a slightly higher discount rate, modestly better projected profit margin, and a somewhat lower future P/E helping to support the unchanged view. What's in the News The largest stroke detection data set to date for the Swoop system was reported.Aggiornamento della narrazione • Feb 18
HYPR: India Approval And Clinical Data Will Support Future Upside Potential
Analysts have modestly revised their price target for Hyperfine to $1.30, reflecting updated assumptions around a slightly lower discount rate, marginally higher revenue growth and profit margin expectations, and a small adjustment to the projected future P/E multiple. What's in the News The largest stroke detection data set for the Swoop system was published in Stroke: Vascular and Interventional Neurology.Aggiornamento della narrazione • Feb 04
HYPR: Growing Clinical Evidence And New Approvals Will Support Upside
Analysts have kept their price target for Hyperfine unchanged at $1.65, reflecting only minor adjustments to underlying model inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The largest-to-date stroke detection study with the Swoop system reported strong sensitivity and specificity for ischemic lesion detection, including very small strokes, with shorter scan times and improved brain image quality in emergency settings (Stroke: Vascular and Interventional Neurology).Aggiornamento della narrazione • Jan 21
HYPR: Expanded Clinical Use And New Regulatory Wins Will Drive Upside
Analysts have modestly adjusted their price target for Hyperfine to US$1.65, reflecting tweaks to key inputs such as a slightly lower discount rate, marginally softer revenue growth and profit margin assumptions, and a higher future P/E expectation. What's in the News Hyperfine enrolled the first patient in the Contrast PMR study, a prospective multi center trial evaluating contrast enhanced ultra low field portable MRI to support a potential future FDA submission to expand Swoop system use with gadolinium based contrast agents.Articolo di analisi • Jan 15
Revenues Tell The Story For Hyperfine, Inc. (NASDAQ:HYPR) As Its Stock Soars 34%
Hyperfine, Inc. ( NASDAQ:HYPR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the...Aggiornamento della narrazione • Jan 06
HYPR: India Approval Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Hyperfine, reflecting small tweaks to the discount rate, revenue growth and future P/E assumptions while keeping fair value steady at US$1.30. What's in the News Hyperfine received regulatory approval in India for its Swoop portable MRI system from the Central Drugs Standard Control Organization, allowing commercialization across the country through a distribution partnership with Radiosurgery Global Ltd.Aggiornamento della narrazione • Dec 18
HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential
Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate. What's in the News Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).Aggiornamento della narrazione • Dec 04
HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside
Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.Aggiornamento della narrazione • Nov 20
HYPR: Expanding Clinical Applications Will Drive 2025 Revenue Acceleration
Narrative Update on Hyperfine: Analyst Price Target Revision Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment. What's in the News Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively.Aggiornamento della narrazione • Nov 05
HYPR: International Approvals And Expanded Use Will Drive Upside Momentum
Narrative Update on Hyperfine Analyst Price Target Analysts have maintained their fair value estimate for Hyperfine at $1.70. They cite largely unchanged growth projections along with only small adjustments in profit margin and discount rate assumptions.Aggiornamento della narrazione • Oct 21
Analysts Lift Hyperfine Price Target Amid Positive Studies and Stronger Revenue Growth Forecast
Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.Articolo di analisi • Oct 07
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump
Despite an already strong run, Hyperfine, Inc. ( NASDAQ:HYPR ) shares have been powering on, with a gain of 30% in the...Aggiornamento della narrazione • Aug 29
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42. What's in the News Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.Aggiornamento della narrazione • Aug 15
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.Articolo di analisi • Jul 23
Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a really impressive month, gaining 46% after a shaky period beforehand...Articolo di analisi • May 16
Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Nuova narrazione • Apr 09
2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption
Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.Articolo di analisi • Mar 22
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a horrible month, losing 28% after a relatively good period beforehand...Articolo di analisi • Feb 05
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have continued their recent momentum with a 25% gain in the last month alone...Articolo di analisi • Nov 15
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. ( NASDAQ:HYPR ) filed its third-quarter result this time last...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$35m |
| Dec 31 2025 | US$897k | US$582k | -US$36m |
| Sep 30 2025 | n/a | n/a | -US$40m |
| Jun 30 2025 | n/a | n/a | -US$39m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$2m | US$568k | -US$41m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$847k | US$550k | -US$44m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$4m | US$95k | -US$73m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$89m |
| Mar 31 2022 | n/a | n/a | -US$81m |
| Dec 31 2021 | US$182k | n/a | -US$65m |
Compensazione vs Mercato: La retribuzione totale di Maria ($USD 896.82K ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 624.15K ).
Compensazione vs guadagni: La retribuzione di Maria è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Maria Degois-Sainz (59 yo)
3.6yrs
Mandato
US$896,817
Compensazione
Ms. Maria Degois-Sainz is Independent Director of Pulse Biosciences, Inc. from January 08, 2026. Ms. Degois-Sainz is Chair of the Board of Onera Technologies B.V. from January 2025. Ms. Degois-Sainz serves...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3.6yrs | US$896.82k | 0.040% $ 59.0k | |
| Founder & Vice Chairman | 12.3yrs | US$50.00k | 16.55% $ 24.3m | |
| Chief Administrative Officer | 3.3yrs | US$799.63k | 0.052% $ 75.7k | |
| Chief Operating Officer | 2.8yrs | US$799.63k | 0.13% $ 193.2k | |
| Vice President of Technology | 1.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Office Strategy and Partnerships | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Hospital Business | 1.3yrs | Nessun dato | Nessun dato | |
| Chief Regulatory & Quality Officer | less than a year | Nessun dato | Nessun dato |
1.5yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di HYPR non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$896.82k | 0.040% $ 59.0k | |
| Founder & Vice Chairman | 12.3yrs | US$50.00k | 16.55% $ 24.3m | |
| Independent Director | 4.8yrs | US$129.29k | 0.021% $ 30.5k | |
| Independent Director | 4.4yrs | US$129.63k | 0.020% $ 29.2k | |
| Independent Chairperson | 4.4yrs | US$197.37k | 0.020% $ 29.2k | |
| Member of Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato |
4.4yrs
Durata media
68yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HYPR sono considerati esperti (durata media dell'incarico 4.4 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 15:09 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Hyperfine, Inc. è coperta da 4 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Vijay Kumar | Evercore ISI |